In this biomarker substudy of the CANVAS trial among participants with T2DM who were at a high risk of or had established ASCVD, higher circulating FGF-23 was associated with an increased risk of the composite of CV death/HHF and HHF whereas higher circulating hsCRP was associated with an increased risk of CV death and MACE, independent of clinical risk factors, and traditional CV and renal biomarkers. Here, FGF23 is linked to type 2 diabetes mellitus.